胃复安联合5-HT3受体拮抗剂在化疗相关恶心呕吐患者中的疗效分析

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (562 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Metoclopramide combined with 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting in patients with advanced cancer chemotherapy and observe their side effects. Methods Advanced cancer patients ineffective with Dolastron, Ondansetron, Tropisetron, and Palonosetron in Center of Oncology of Renming Hospital of Wuhan University from October 2016 to May 2018 were selected respectively, with 30 cases in each variety, named group A, B, C, and D group. Then they were treated combined with Metoclopramide. The occurrence of nausea and vomiting and other side effcts in each group were observed. Results There were no statistically significant differences in the effectiveness of the four groups in preventing acute and delayed nausea and vomiting (P ＞ 0.05). The most common side effects of the four groups were headache, constipation, bloating, drowsiness, fatigue, dizziness, and thirst, but they could be alleviated after symptomatic treatment or withdrawal. Conclusion Among advanced cancer patients who were ineffective with 5-HT3 receptor antagonist alone, Metoclopramide combined with Dolastreline, Ondansetron, Tropisetron, and Palonosetron work in some patients and reduces the incidence of side reactions, which has positive clinical significance.

Key words： Chemotherapy-induced nausea and vomiting Metoclopramide 5-HT3 receptor antagonists Chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yuanshi CHEN Xin WU Long XU Ximing

Cite this article:

LIU Yuanshi CHEN Xin WU Long XU Ximing. Observation and analysis of Metoclopramide combined with 5-HT3 receptor antagonist in patients with chemotherapy-induced nausea and vomiting[J]. 中国医药导报, 2019, 16(14): 83-87.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I14/83

[1] Koth SM，Kolesar J. New options and controversies in the management of chemotherapy-induced nausea and vomiting [J]. Am J Health Syst Pharm，2017，74（1）：812.
[2] Sheikhi MA，Ebadi A，Talaeizadeh A，et al. Alternative Methods to Treat Nausea and Vomiting from Cancer Chemotherapy [J]. Chemother Res Pract，2015，2015（1）：1-6.
[3] Hori K，Kobayashi N，Atsumi H，et al. Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting：a nationwide survey using a distributed research network [J]. Support Care Cancer，2014，22（4）：969-977.
[4] Hilarius DL，Kloeg PH，Wall EVD，et al. Chemotherapy-induced nausea and vomiting in daily clinical practice：a community hospital-based study [J]. Support Care Cancer，2012，20（1）：107-117.
[5] 朱秀辉.托烷司琼联合胃复安预防肿瘤化疗恶心、呕吐疗效的观察与护理[J].西南军医，2010，12（4）：667-669.
[6] Artemisia P，Stavros G，Emmanuel L，et al. Granisetron versus tropisetron in the prevention of postoperative nausea and vomiting after total thyroidectomy [J]. Saudi J Anaesth，2013，7（1）：68-74.
[7] Navari RM，Nagy CK，Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy [J]. Support Care Cancer，2013，21（6）：1655-1663.
[8] Egerton-Warburton D，Meek R，Mee MJ，et al. Antiemetic use for nausea and vomiting in adult emergency department patients：randomized controlled trial comparing ondansetron，metoclopramide，and placebo [J]. Ann Emerg Med，2014，64（5）：526.
[9] Hesketh PJ. Chemotherapy-based treatment of chemotherapy-induced nausea and vomiting [J]. N Engl J Med，2008，358（23）：2482.
[10] Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting-two new agents [J]. J Support Oncol，2013，1（2）：89-103.
[11] Trigg ME，Higa GM. Chemotherapy-induced nausea and vomiting：antiemetic trials that impacted clinical practice [J]. J Oncol Pharm Pract，2010，16（4）：233.
[12] 李晨蔚，励新健，周增辉.盐酸托烷司琼预防化疗所致恶心呕吐的疗效观察[J].现代实用医学，2008，20（11）：881-882.
[13] 袁芳.肺癌患者化疗所致呕吐的药物预防方案[J].实用癌症杂志，2015，30（5）：765-767.
[14] Miner WD，Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism [J]. Br J Pharmacol，1986，88（3）：497.
[15] Horn CC，Ciucci M，Chaudhury A. Brain Fos expression during 48 h after cisplatin treatment：Neural pathways for acute and delayed visceral sickness [J]. Auton Neurosci，2007，132（1/2）：44.
[16] Babic T，Browning KN. The role of vagal neurocircuits in the regulation of nausea and vomiting [J]. Eur J Pharmacol，2014，722（1433）：38.
[17] Jin Y，Sun W，Gu D，et al. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting：a meta-analysis [J]. Eur J Cancer Care（Engl），2013，22（1）：41-50.
[18] Hesketh PJ，Bohlke K，Lyman GH，et al. Antiemetics：American Society of Clinical Oncology Focused Guideline Update [J]. J Clin Oncol，2016，34（4）：381.
[19] Navari RM. Management of Chemotherapy-Induced Nausea and Vomiting [J]. Drugs，2013，73（3）：249-262.
[20] 余建家.托烷司琼联合胃复安预防肿瘤化疗恶心、呕吐疗效分析[J].中外医学研究，2013（32）：23-24.
[21] 陈飞，程祺，杨雅雯.托烷司琼针、甲氧氯普胺针独用及合用对肿瘤化疗恶心、呕吐的预防效果评价[J].中国医药科学，2015，5（24）：48-50.
[22] Fabi A，Malaguti P. An update on palonosetron hydrochloride for the treatment of radio/ chemotherapy-induced nausea and vomiting [J]. Expert Opin Pharmacother，2013， 14（5）：629.
[23] Celio L，Agustoni F，Ricchini F，et al. Palonosetron plus dexamethasone in highly emetogenic chemotherapy：pooled data from two phase Ⅲ trials [J]. Future Oncol，2013，9（10）：1451-1458.
[24] 张童童，李青.神经激肽1受体阻断剂——缓解化疗所致恶心呕吐的新选择[J].癌症进展，2013，11（4）：351-354.
[25] 程艳.维生素B6、胃复安足三里穴位注射防治顺铂化疗致呕吐的观察及护理[J].中国实用医药，2013，8（7）：247.
[26] 李云华，高福泉，杨鲁华，等.洁白胶囊预防肺癌化疗恶心呕吐的临床疗效观察[J].临床荟萃，2003，18（10）：586-587.